New! View global litigation for patent families

US3468887A - Process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2 - Google Patents

Process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2 Download PDF

Info

Publication number
US3468887A
US3468887A US67775567A US3468887A US 3468887 A US3468887 A US 3468887A US 67775567 A US67775567 A US 67775567A US 3468887 A US3468887 A US 3468887A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
acid
gm
example
point
melting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Helmut Stahle
Karl Zeile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Boehringer Ingelheim GmbH
Original Assignee
CH Boehringer Sohn AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with heteroatoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/14Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached to said nitrogen atoms

Description

3,468,887 PROCESS FOR THE PREPARATION OF Z-PHENYL- AMINO-1,3-DIAZACYCLOALKENES-2 Helmut Stable and Karl Zeile, Ingelheim am Rhein, Germany, assignors to Boehringer Ingelheim G.m.b.H., llngelheim am Rhein, Germany, a corporation of Germany No Drawing. Filed Oct. 24, 1967, Ser. No. 677,755 (Ilairns priority, application Germany, Oct. 31, 1966, B 89,635; Sept. 27, 1967, B 94,681 Int. Cl. C07d 49/30, 49/00; A61k 27/00 US. Cl. 260-253 6 Claims ABSTRACT OF THE DISCLOSURE An improved process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2 comprising reacting an alkylene diamine with a phenylimino carbonic acid derivative and 2-phenylamino-1,3-diazacycloalkenes-2 having useful pharmacological properties, a blood-pressure reducing activity.

PRIOR ART Belgian Patent No. 623,305 describes a process for the preparation of certain Z-arylamino-1,3-diazacycloalkenes- 2 by heating a'lkylenediam'mes with an arylisothiuronium salt at 100 to 200 C. in the absence of a solvent. The said process results in relatively good yields for certain compounds and made possible the production of 2-(2,6- disubstituted phenylamino)-l,3-diazacyclopentenes-2, particularly the 2,6-dichlro compound which is a valuable blood pressure reducing agent. However, the said process cannot be used to make many 2-phenylamino-1,3-diazacycloalkenes-Z and requires relatively high temperatures and prolonged reaction periods.

OBJECTS OF THE INVENTION It is an object of the invention to provide a novel improved process for the preparation of 2-phenylamino- 1,3-diazacycloalkenes-2.

It is another object of the invention to provide novel 2-phenylamino1,3-diazacycloalkenes-2.

These and other objects and advantages of the invention will become obvious from the following detailed description.

THE INVENTION The novel 2-phenylamino-1,3-diazacycloalkenes-2 of the invention are selected from compounds of the formula wherein n is a whole integer from 2 to and when n is 2, R is selected from the group consisting of nitro, cyano and amino and R and R are selected from the group consisting of hydrogen, halogen and alkyl of 1 to 4 carbon atoms with the proviso that R may be halogen when R and R are both halogen and when n is an integer from 3 to 5, R is hydrogen and R and R are selected from the group consisting of halogen and alkyl of 1 to 4 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts. A particularly preferred group of compounds are those in which n is 2 and R R and R are halogen, particularly bromine and/ or chlorine.

Examples of suitable acids for the non-toxic, pharmaceutically acceptable acid addition salts are inorganic acids such as hydrogen halides, phosphorous acid, nitric acid, sulfuric acid, etc., and organic acids such as acetic acid, propionic acid, lactic acid, maleic acid, fumaric acid,

nited States Patent 0 ice citric acid, tartaric acid, methane sulfonic acid, 8-chlorotheophylline, etc.

The novel 2-phenylamino-1,3-diazacycloalkenes-2 of the invention possess valuable pharmaceutical properties, namely a blood-pressure reducing activity. In addition, some of the said compounds also possess sedative, vasconstrictive and/ or secretion-inhibiting properties.

The novel process of the invention for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2 of the formula wherein Ar is phenyl which may be substituted with at least one substituent selected from the group consisting of alkyl of 1 to 4 carbon atoms, trifluoromethyl, halogen, cyano and nitro and n is an integer between 2 to 5 comprises reacting an alkylene-diamine of the formula wherein n has the above definition with a compound of the formula wherein Ar has the above definition, X is selected from the group consisting of halogen, lower alkylthio and lower alkoxy of l to 7 carbon atoms and NH and Y is halogen with the provisos that Y may be lower alkoxy when X is NI-I and may be lower alkylthio when X is lower alkylthio to form the corresponding 2-phenylamino-l,3- diazacycloalkene-Z. The said product can be converted into its acid addition salt by reacting the compound of Formula II with the desired acid.

The said reaction is preferably performed under anhydrous conditions in an inert organic solvent such as lower alkyl ethers like ethyl ether and aromatic hydrocarbons like benzene, toluene, etc. The reaction temperatures will depend upon the particular reactants but is usually between 10 to 30 C., preferably 0-l5 C. The preferred compounds of Formula IV are those where X and Y are both halogens, particularly bromine and/ or chlorine.

As a modification of the process of the invention to produce Z-(aminophenylamino)-l,3-diazacycloalkenes-2, the corresponding nitro compound produced as described above is converted into an amino compound by known methods such as hydrogenation with a Raney-nickel catalyst.

The process of the invention has the advantage of being performed in one step at low reaction temperatures in short reaction times. For example, the reaction of an alkylene diamine with a phenyl-isocyanide dichloride takes place immediately without heating in contrast to the process of Belgian Patent No. 623,305 which requires to 200 C. temperatures. This results in considerable saving in plant equipment and energy consumption.

Some of the starting compounds of Formula IV are known from DBP No. 1,094,737 and No. 1,138,039, British Patent No. 888,646 and French Patent No. 1,25 6,- 873 or can be prepared by the processes described in said patents. To prepare compounds of Formula 1V in which at least one of X and Y is other than halogen, compounds of Formula IV with X and Y halogen are reacted with a lower alkanol or lower alkyl mercaptan or ammonia.

The novel therapeutic compositions of the invention are comprised of at least one compound of Formula I or their non-toxic, pharmaceutically acceptable acid addition salts and a pharmaceutical carrier. The said compositions are preferably made up for oral or parenteral administration.

Solid compositions for oral administration include compressed tablets, pills and granules. In these compositions one or more of the compounds of general Formula I are mixed with at least one inert diluent, such as calcium carbonate, starch, alginic acid or lactose. Besides inert diluents, the compositions may also comprise additional substances, for example lubricating agents such as magnesium stearate. Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. These contain inert diluents such as water, they may also comprise adjuvants, such as wetting and suspending agents, as well as sweetening and flavouring agents. Further compositions for oral administration are capsules of absorbable material such as gelatin, containing one or more of the active substances with or without the addition of diluents or excipients.

For parenteral administration, the compositions include sterile aqueous or non-aqueous solutions, emulsions or suspensions. As non-aqueous suspending media may, for example, be used propylene glycol, polyethylene glycol or vegetable oils. Such compositions may also contain adjuvants, such as Wetting, emulsifying and dispersing agents. They may be sterilized in conventional manners. Besides they may be produced in the form of sterile solid compositions, soluble in sterile Water or some other sterile injectable medium immediately before they are applied.

All composition forms may contain further active ingredients, such as diuretics or other hypotensive agents. Suitable preparations of the said compositions contain from 0.1 to 100 mg., preferably 0.5 to 50 mg. per dosage unit of the active ingredients.

The novel method of the invention comprises administering to warm-blooded animals an eifective amount of at least one compound of Formula I or their acid addition salts. The usual useful dose is 0.0083 to 0.83 mg./kg. of body weight.

In the following examples there are described several preferred embodiments to illustrate the invention. However, it should be understood that the invention is not intended to be limited to the specific embodiments.

Example I.Preparation of 2-(2,6'-dichlorophenylamino)-l,3-diazacyclopentene-2 Step A: Preparation of 2,6-dichlorophenylformamide. A solution of 100 gm. of 2,6-dichloroaniline in 200 gm. of formic acid was refluxed for four hours at 100 C. as described in French Patent No. 1,341,781 and then was cooled and poured onto ice. The precipitate was vacuum filtered, washed with Water and petroleum ether (boiling point of 40 C.), dried over P and recrystallized from 300 ml. of 1:1 benzene-ethanol mixture to obtain 69 gm. (64.6% yield) of 2,6-dichlorophenyl formamide having a melting point of 176-1765 C.

Step B: Preparation of 2,6-dichlorophenyl-isocyanidedichloride-19 gm. (0.1 mole) of 2,6-dichlorophenylformamide were added to a solution of 13.5 gm. of sulfonyl chloride in 30 cc. of thionyl chloride at a temperature below C. as described in German Patent No. 1,094,737 and a thick crystal mass formed in a very short time. Then, the reaction mixture was heated at 55 to 60 C. for 10 hours whereby the crystal mass gradually liquified with evolution of HCl and S0 The insoluble material was filtered olf and the filtrate was evaporated to dryness under water-jet vacuum to remove excess thionyl chloride. The residue was fractionally distilled under high vacuum to obtain 10.2 gm. (42.0% yield) of colorless 2,6-dichlorophenyl-isocyanide dichloride having a boiling point of 65-68 C. at 0.02 mm. Hg.

Step C: Preparation of 2-(2',6'-dichlorophenylamino)- 1,3-diazacyclopentene-2 and its hydrochloride.--7.3 gm. (0.03 mole) of 2,6-dichlorophenyl-isocyanide dichloride were dissolved in 20 cc. of benzene and 1.8 gm. (0.03 mole) of ethylenediamine were slowly added thereto at 5 to 10 C. The resulting liquid suspension was allowed to stand for 2 hours at room temperature during which a thick white crystal mass (2.15 gm. having a melting point of 317318 C.) was formed which was filtered otf. The filtrate was admixed with petroleum ether (boiling point 4080 C.) and the precipitate was filtered, washed with petroleum ether and dried to obtain 2.5 gm. (36.6% yield) of 2-(2',6'-dichlorophenylamino)1-3-diazacyclopentene-2 having a melting point of 136138 C.

The free base was dissolved in 200 cc. of ether and the resulting solution was filtered to remove any insoluble material and then mixed with ethereal hydrochloric acid to obtain a pH of about 4. The hydrochloride salt of the free base precipitated, was filtered and dried to obtain 2.6 gm. (33.2% yield) of the said hydrochloride. The hydrochloride thus obtained proved to be identical by thin layer chromatogram, IR-spectrum and elementary analysis with a 2-(2,6'-dichlorophenylamino)-l,3-diazacyclopentene-(2), obtained according to the process or" the Belgian Patent No. 623,305 and the mixed melting point with such a product did not show any depression.

Example II.Preparation of 2-(2,6-dichlorophenylamino)-1,3-diazacyclopentene-2 Step A: Preparation of 2,6-dichlorophenyliminomethylchlorocarbonate.12.15 gm. (0.05 mole) of 2,6- dichlorophenylisocyanide dichloride were dissolved in 20 cc. of absolute methanol and a solution of 1.15 gm. (0.05 mole) of sodium in 20 cc. of absolute methanol was added thereto with stirring and ice cooling over 45 minutes. The sodium chloride formed was filtered off and the filtrate was evaporated under vacuo to dryness and then fractionally distilled to obtain 9.2 gm. of pure 2,6- dichlorophenylimino-methylchlorocarbonate having a boiling point of 6-568 C. at 0.02 mm. Hg.

Step B: Preparation of 2-(2.,6-dichlorophenylamino 1,3-diazacyclopentene-2-HCl.-4.0 gm. (0.016 mole) of 2,6-diohloro-phenylimino methylchloro carbonate were dissolved in 40 cc. of absolute benzene and a solution of 1.0 gm. (0.016 mole) of ethylenediamine in 20* cc. of benzene was added thereto dropwise at 10 C. After stirring the reaction mixture for one hour at room temperature, it was heated at reflux for 5 hours. The White by-product was filtered oif and the filtrate was extracted with 2 N hydrochloric acid. The aqueous hydrochloric acid extracts were extracted with ether at varying pHs and the ethereal extracts having a pH greater than 7 contained the desired product and a small amount of impurity.

The basic solutions were dried over magnesium sulfate and adjusted to a pH of about 4 with ethereal hydrochloric acid. The precipitate was recrystallized 3 times from methanol ether to obtain pure 2-(2',6'-dichlorophenylamino)-l,3-diazacyclopentene-2 hydrochloride having a melting point of 316318 C.

Example III Step A: Preparation of 2-(2',6-dichlorophenylamino)- l,3-diazacyclopentene-2.A solution of 4.2 gm. (0.05 mole) of sodium ethyl mercaptide in 20 cc. of methanol was added slowly at 10 C., with stirring to a solution of 12.15 gm. (0.05 mole) of 2,6-dichlorophenylisocyanide dichloride in 30 cc. of absolute benzene and the mixture was allowed to stand overnight. The precipitated sodium chloride was filtered off and the solvent was removed from the filtrate by vacuum distillation. The partly crystalline residue was admixed with petroleum ether (boiling point of 40 C.), the insoluble material was filtered off and the filtrate was evaporated under vacuum to dryness to obtain 6.0 gm. of 2,6-dichlorophenylimino-ethylchlorothiocarbonate.

Step B: Preparation of 2-(2',6'-dichlorophenylamino)- 1,3-diazacyclopentene-2.-5.5 gm. (0.02 mole) of 2,6-dichlorophenylimino-ethylchlorothiocarbonate were dissolved in 30 cc. of absolute benzene and a solution of 1.4 ml. (0.02 mole) of ethylenediamine in 20 cc. of absolute benzene was added dropwise thereto with stirring at C. The reaction mixture was allowed to stand at room temperature over night and then was heated at reflux for 5 hours. The benzene solution was cooled and extracted with 1 N hydrochloric acid. The aqueous phase was then extracted with ether at varying pH values and the ether extracts having a pH higher than 6.5 were combined and dried. The ether solution was adjusted to a pH of about 4 by the addition of ethereal hydrochloric acid and the resulting precipitate was recrystallized from a small amount of methanol-water to obtain 50 mg. of pure 2- (2,6-dichlorophenylamino l ,3-diazacyclopentene-2 hydrochloride having a melting point of 315-318" C.

Example lV.--Preparation of 2-(2'-nitrophenylamino)- 1,3-diazacyclopentene-2 27.5 gm. of 2-nitrophenylisocyanide dichloride, prepared by the process of German Patent No. 1,094,737, were dissolved in 70 cc. of absolutebenzene and a mixture of 10 cc. of ethylenediamine and cc. of absolute benzene was added dropwise thereto at 5 to 10 C. to form a viscous, brown suspension which was allowed to stand overnight at room temperature. The suspension was made acid with dilute hydrochloric acid and the insoluble residue was filtered oil. The filtrate was extracted with ether at varying pH values and the ether extracts having a pH of morethan 6 were combined, dried and adjusted a pH of about 4 by the addition of ethereal hydrochloric acid to obtain 2-(2'-nitrophenylamino)-1,3-diazacyc1opentene- 2 hydrochloride having a melting point of 227 to 229 C.

Example V Using'the procedure of Example IV, there were obtained 9.5 gm. (39.5% yield) of 2-(2-chloro-4-nitrophenylamino)-l,3-diazacyclopentene-2 having a melting point of,-229'23l C. and whose hydrochloride had a melting point of 262264 C. after recrystallization of methanol-ether (1:3).

Example VI Using the procedure of Example IV, there were obtained 6.3 gm. (19.0% yield) of 2-(2-methyl-4'-nitrophenylamino)-l,3-diazacyclopentene-2 having a melting point of. l8l-185 C. and whose hydrochloride had a melting point of 207210 C.

Example VII.-Preparation of 2-(4-amino-2'- chlorophenylamino)-1,3-diazacyclopentene-2 7.2 gm. (0.03 mole) of 2-(2-chloro-4-nitrophenylamino)-l,3-diazacyclopentene-2, prepared as in Example V, in a mixture of methanol and monomethyl ether of glycol were hydrogenated with a Raney nickel catalyst until 2.24 liters of hydrogen at 22 C. and 734 torr had been taken up. The hydrogenation was then stopped and the catalyst was filtered off. The filtrate was evaporated to dryness and the residue was dissolved in dilute hydrochloric acid. The solution was extracted with ether and the equeous acid phase was treated with activated charcoal, made alkaline with 5 N sodium hydroxide and extracted successively with ether, chloroform and ethyl acetate. The chloroform and ethylacetate phases were combined, dried and adjusted to a pH of about 4 with ethereal hydrochloric acid. The precipitate was filtered, washed with ether and dried to obtained 2.3 gm. (27% Yield) of dihydrochloride of 2-(2'-chloro-4'-aminophenylamino)- l,3-diazacyclopentene-2 having a melting point of 273- 276 C. after recrystallization from methanol-ether.

Example VIIII Using the procedure of Example VII, there was obtained a 23.7% yield of 2-(2-methyl-4-aminophenylamino)-l,3-diazacyclopentene-2 having a melting point of 27828l C.

Example IX Using the procedure of Example VII, there was obtained from 2 (4 nitro 2',5' dichlorophenylamino) 1,3- diazacyclopentene 2,2 (4-amino-2,5-dichlorophenylamino)-l,3-diazacycl0pentene-2 having a melting point of l55-l57 C. and whose nitrate salt had a melting point of 186-1865 C.

Example X.Preparation of 2-(2',4,6'-trichlorophenylamino) l ,3-diazacyclopentene-2 A mixture of 14 gm. (0.05 mole) or 2,4,6-trichloro phenylisocyanide dichloride (boiling point of l43145 C. at 14 torr) and 25 cc. of absolute benzene was added dropwise over 30 minutes at 10 C. to a mixture of 5 cc. of ethylenediamine and 50 cc. of absolute benzene. The reaction mixture was evaporated to dryness and the residue was stirred with petroleum ether (boiling point 40-80" C.). The petroleum ether was filtered ofl and the 11.5 gm. of residue was dried and dissolved in dilute hydrochloric acid. The insoluble residue filtered oil and the bright filtrate was extracted repeatedly with ether at pH of 5 to 7 which removed impurities. The aqueous phase was made alkaline with dilute sodium hydroxide and the precipitate found was vacuum filtered, Washed with water and dried to obtain 3.5 gm. (26.5% yield) of 2-(2,4,6-trichlorophenylamino) 1,3 diazacyclopentene-2 having a melting point of 174-176 C. and whose hydrochloride had a melting point of 269270 C.

Example XI Using the procedure of Example X, there was obtained 2 (2,4,5 trichlorophenylamino) 1,3 diazacyclo pentene-2 whose nitrate had a melting point of 182-183 C. (decomp.).

Example XII Using the procedure of Example X, there was obtained 2 (2',4',6 tribromophenylamino) 1,3 diazacyclopentene-Z Whose nitrate had a melting point of 215 C. (decomp.).

Example XlII.-Preparation of 2-(4'-cyanophenylamino) -1,3-diazacyclopentene-2 40 gm. (0.20 mole) of 4-cyanophenylisocyanide dichloride dissolved in 200 cc. of absolute benzene were added dropwise to a solution of 20 cc. (0.30 mole) of ethylene diamine in 50 cc. of absolute benzene and then the resulting reaction mixture was evaporated in vacuo. The residue was dissolved in dilute hydrochloric acid and the solution was filtered to remove insoluble material. The clear, colorless filtrate was made alkaline with dilute sodium hydroxide and the precipitate formed was filtered, washed with water and dried to obtain 34.0 gm. (91.5% yield) of 2 (4-cyanophenylamino)1,3-diazacyclopentone-2 having a melting point of 2435-245 C. and whose hydrochloride had a melting point of 254-255 C,

Example XIV.Preparation of 2-(2,3'-dichlorophenylamino 1,3-diazacyclohexene-2 A mixture of 7.4 gm. (0.1 mole) of 1,3-diaminopropane and cc. of absolute benzene was added dropwise with stirring over 1 hour at 5 C. to a solution of 24.3 gm. (0.1 mole) of 2,3-dichlor0phenylisocyanide dichloride in cc. of absolute benzene whereby a yellowish White precipitate formed. The solvent was removed by evaporation in vacuo and the residue was dissolved in 2 N hydrochloric acid. The insoluble residue was filtered off and the filtrate was made alkaline with 2 N sodium hydroxide whereby a precipitate formed which was filtered, washed with water and dried to obtain 2-(2,3'-dichlorophenyl amino)-1,3-diazacyclohexene-2 having a melting point of 161-162 C. and whose hydrochloride had a melting, point of 243-245 C.

Example XV.Preparation of 2-(2',6-dichlorophenylamino)-1,3-diazacycloheptene-2 4 gm. (0.045 mole) of 1,4-diaminobutane dissolved in 50 cc. of absolute benzene were added dropwise with stirring to a solution of 7.3 gm. (0.03 mole) of 2,6-dichlorophenylisocyanide dichloride in 50 cc. of absolute benzene at 5 to C. and the resulting suspension was allowed to stand overnight at room temperature. The suspension was filtered and the filtrate was evaporated to dryness in vacuo. The viscous oil residue was dissolved in dilute hydrochloric acid and the solution was filtered to remove insoluble residue. The solution was extracted with ether at varying pH values and the ether extracts at a pH higher than 7 were combined, dried and the pH was adjusted to about 4 by the addition of ethereal hydrochloric acid. The precipitate was filtered, washed and dried to obtain 1.4 gm. (15.8% yield) of 2-(2,6'-dichlorophenylamino)-l,3-diazacycloheptene-2 hydrochloride having a melting point of 3 14-3 16 C.

Example XVI Using the procedure of Example XV, there was obtained the nitrate of 2-(2,3'-dichlorophenylamino)-l,3- diazacycloheptene-2 having a melting point of 228- 230 C.

Example XVII Using the procedure of Example XV, there was obtained the nitrate of 2-(2',4'-dimethylphenylamino)-1,3- diazacycloheptene-Z having a melting point of 180- 185 C.

Example XVIII Using the procedure of Example XV, there was obtained the nitrate of 2-(2-chloro-4-methyl-phenylamino)- 1,3-diazacycloheptene-2 having a melting point of 195 C.

Example XIX.-Preparation of 2-(2,6-dichlorophenylamino)-l,3-diazacyclooctene-2 3.24 gm. (105%) of 1,5-diaminopentane dissolved in 50 cc. of absolute benzene were added dropwise with stirring at 510 C. to a solution of 7.3 gm. (0.03 mole) of 2,6-dichlorophenyl isocyanide dichloride in 50 cc. of absolute benzene and the mixture was allowed to stand overnight at room temperature. The solvent was evaporated olf in vacuo and the residue was dissolved in dilute hydrochloric acid. The insoluble portion was filtered off and the filtrate was extracted with ether at varying pH values. The ether extracts having a pH greater than 7 were combined, dried over MgSO and adjusted to a pH of about 4 with concentrated nitric acid. The precipitate was filtered oflF, washed and dried to obtain the nitrate of 2-(2,6'-dichlorophenylamino)-1,3-diazacyclooctene-2 having a melting point of 263 C.

PHARMACOLOGICAL COMPOSITIONS Example ATablets Ingredients: Parts 2-(2,4,6' trichlorophenylamino) 1,3 diazacyclopentene-(2)-HC1 0.2 Lactose 54.8 Maize starch 30.0 Soluble starch 4.0 Magnesium stearate 1.0

90.0 Example BTablets Ingredients: Parts 2-(2'-chloro 4' nitrophenylamino)-l,3-diazacyclopentene-(2)-HC1 0.8 Lactose 54.2 Maize starch 30.0 Soluble starch 4.0 Magnesium stearate 1.0

The individual ingredients were thoroughly admixed with each other and the intimate mixture is pressed in conventional fashion into 90.0 mg. tablets.

Example CDrops (0.2 mg. in l ml.=20 drops) Ingredients: Parts 2-(2,4,5-trichlorophenylamino) 1,3 diazacyclopentene-(2)-HNO 0.02 Methyl-p hydroxybenzoate 0.07 Propyl-p-hydroxybenzoate 0.03 Demineralised water, ad 100.

Example DAmpoules Ingredients: Parts 2-(2,4',6'-trichlorophenylamino) 1,3 diazacyclopentene-(2)-HCl 0.50 Sodium chloride 18.0 Dist. water, ad 2.

PHARMACOLOGICAL DATA Using the test procedure of French BSM 21 54 the blood pressure reducing activity of 2-(2,4,6-'trichlorophenylamino)-l,3-diazacyclopentene-2 hydrochloride was determined on rabbits in urethane narcosis. {The said compound was administered intravenously and the blood pressure reduction was measured with a mercury manometer on the arteria carotis. The results are summarized in Table I. Not only was the reduction in the blood'pressure rapid, the full effect thereof lasted for several hours.

TABLE I 30 300 l, 000 4 6 5 It cyano and nitro and n is an integer between 2 to 5 which comprises reacting an alkylenediamine of the formula wherein n has the above definition with a compound of the formula wherein Ar has the above definition, X is selected from the group consisting of halogen, lower alkylthio and lower alkoxy of 1 to 7 carbon atoms and NH and Y is halogen with the provisos that Y may be lower alkoxy when X is NH and may be lower alkylthio when X is lower alkylthio to form the corresponding 2-phenylamino-l,3- diazacycloalkene-2.

2. The process of claim 1 wherein the Ar is substituted with a nitro group and the 2-(nitrophenylamino)-l.3- diazacycloalkene-Z is hydrogenated in the presence of a Raney nickel catalyst to form the corresponding Z-(aminophenylamino)-1,3-diazacycloalkene-2.

3. The process of claim 1 wherein the 2-phenylamino- 1,3-diazacycloalkene-2 is reacted with a non-toxic, pharmaceutically acceptable acid to form the corresponding acid addition salt.

4. The process of claim 1 wherein X and Y are chlorine.

5. The process of claim 1 wherein n is 2. 6. The process of claim 1 wherein the reaction is elfected in an inert organic solvent.

References Cited UNITED STATES PATENTS 1 Bloom 260309.6

Bloom 260256.4 Fruhstorfer et al. 260309.6 Zeile et a1. 260256.4

Z8118 et al. 260309.6 1

HENRY R. J ILES, Primary Examiner 0 NATALIE TROUSOF, Assistant Examiner US. Cl. X.R.

US3468887A 1966-10-31 1967-10-24 Process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2 Expired - Lifetime US3468887A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE1966B0089635 DE1670162C3 (en) 1966-10-31 1966-10-31
DEB0094681 1967-09-27

Publications (1)

Publication Number Publication Date
US3468887A true US3468887A (en) 1969-09-23

Family

ID=25968163

Family Applications (1)

Application Number Title Priority Date Filing Date
US3468887A Expired - Lifetime US3468887A (en) 1966-10-31 1967-10-24 Process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2

Country Status (8)

Country Link
US (1) US3468887A (en)
BE (1) BE705944A (en)
DE (1) DE1670274A1 (en)
DK (1) DK124404B (en)
ES (1) ES346635A1 (en)
FR (1) FR7534M (en)
GB (1) GB1180766A (en)
NL (1) NL6714808A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931152A (en) * 1974-01-29 1976-01-06 American Cyanamid Company 2-(1,3-Diazacycloalkenyl)-2-hydrazones of substituted chalcones
US4213995A (en) * 1978-02-17 1980-07-22 Boehringer Ingelheim Gmbh 2-Phenylimino-imidazolidines and salts thereof
US4250186A (en) * 1978-02-17 1981-02-10 Boehringer Ingelheim Gmbh Method of slowing heart rate
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
US4644007A (en) * 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US5223498A (en) * 1989-02-16 1993-06-29 The Boots Company Plc Phenylamidine and phenylguanidine derivatives and their use as antidiabetic agents
US5502052A (en) * 1988-04-26 1996-03-26 Alcon Laboratories, Inc. Use of a combination of apraclonidine and timolol to control intraocular pressure
US5523316A (en) * 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
US5605922A (en) * 1992-10-13 1997-02-25 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036972A (en) * 1973-02-23 1977-07-19 Boehringer Ingelheim Gmbh 2-(N-thienylmethyl-phenylamino)-imidazolines-(2) and salts thereof
NL7711390A (en) * 1977-10-18 1979-04-20 Philips Nv New 2-arylimino-and hexahydopyrimidinen - imide dazolidinen, salts and complexes thereof, working method for the preparation of the new compounds, as well as fungicidal compositions on the basis of the new compounds.
FR2407919A1 (en) * 1977-11-07 1979-06-01 Hoffmann La Roche New derivatives of 2-imino-imidazolidine, their preparation and their use as a drug
EP0043659B1 (en) * 1980-07-09 1985-02-06 Beecham Group Plc Clonidine derivatives useful in the treatment of diarrhoea
CA1201066A (en) * 1981-11-20 1986-02-25 Alcon Laboratories, Inc. N-¬3,5-dichloro-4-(2-imidazolidinylideneamino)- phenyl|-acetamide solutions for lowering intraocular pressure

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899434A (en) * 1959-08-11 Z-phenylamino-l
US2899426A (en) * 1959-08-11 Synthesis of l
CA625631A (en) * 1961-08-15 Chas. Pfizer And Co. Derivatives of diazacycloalkenes
US3147275A (en) * 1964-09-01 Nh-cha
US3202660A (en) * 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899434A (en) * 1959-08-11 Z-phenylamino-l
US2899426A (en) * 1959-08-11 Synthesis of l
CA625631A (en) * 1961-08-15 Chas. Pfizer And Co. Derivatives of diazacycloalkenes
US3147275A (en) * 1964-09-01 Nh-cha
US3202660A (en) * 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931152A (en) * 1974-01-29 1976-01-06 American Cyanamid Company 2-(1,3-Diazacycloalkenyl)-2-hydrazones of substituted chalcones
US4250186A (en) * 1978-02-17 1981-02-10 Boehringer Ingelheim Gmbh Method of slowing heart rate
US4293564A (en) * 1978-02-17 1981-10-06 Boehringer Ingelheim Gmbh 2-(3,5-Dibromo-4-amino-phenylimino)-imidazolidine, salts and compositions thereof
US4213995A (en) * 1978-02-17 1980-07-22 Boehringer Ingelheim Gmbh 2-Phenylimino-imidazolidines and salts thereof
US4644007A (en) * 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US5502052A (en) * 1988-04-26 1996-03-26 Alcon Laboratories, Inc. Use of a combination of apraclonidine and timolol to control intraocular pressure
US5223498A (en) * 1989-02-16 1993-06-29 The Boots Company Plc Phenylamidine and phenylguanidine derivatives and their use as antidiabetic agents
US5605922A (en) * 1992-10-13 1997-02-25 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5811443A (en) * 1992-10-13 1998-09-22 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5523316A (en) * 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP

Also Published As

Publication number Publication date Type
DE1670274A1 (en) 1970-07-16 application
FR7534M (en) 1969-12-22 grant
NL6714808A (en) 1968-05-01 application
BE705944A (en) 1968-04-30 grant
ES346635A1 (en) 1969-05-16 application
GB1180766A (en) 1970-02-11 application
DK124404B (en) 1972-10-16 grant

Similar Documents

Publication Publication Date Title
US3594380A (en) Isoquinolin-1(2h)-ones
US3391189A (en) Nu-allyl-guanidines and salts thereof
US3335134A (en) Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3303199A (en) Certain imidazolone derivatives and process for making same
US3529019A (en) Alkylaryloxy alanines
US3424762A (en) Certain 3-ureidopyrrolidines
US3644414A (en) 1-substituted-3-phenylpyrrolidines
US3424761A (en) 3-ureidopyrrolidines
US3687965A (en) Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
US3406168A (en) Novel 5, 6-dihydro-6-oxo-11h-pyrido [2, 3-b] [1, 4]benzodiazepines
US3424760A (en) 3-ureidopyrrolidines
US3253037A (en) N-2-alkynyl-amino-benzocylo-alkanes
US3454554A (en) Aminoalkyliminodibenzyl compounds
US3560501A (en) Process for making dihydroquinazolines
US3300494A (en) Pyrazinamidoguanidine products
US4002766A (en) Antiarrhythmia methods
US3908013A (en) Pharmaceutical aromatic guanidine compositions and methods of using same
US3732247A (en) 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
US3769427A (en) Pharmaceutical compositions and methods of using same
US2982783A (en) Amevoevdanes
US4234595A (en) 3-Indolyl-tertiary butylaminopropanols
US3933802A (en) New sulphamoylbenzoic acid amides
US4146647A (en) Substituted phenyl-amidines